334 results about "Nicotinamide mononucleotide" patented technology

The present invention provides a method of treating a mammal having a neuropathophysiological condition, comprising the step of administering to the mammal in need of such treatment a compound selected from nicotinamide or salts or prodrugs thereof, nicotinamide mononucleotide or salts or prodrugs thereof, nicotinamide adenine dinucleotide or salts or prodrugs thereof, nicotinamide riboside nicotinamide or salts or prodrugs thereof, phosphoribosyltransferase, or combinations thereof. Further provided is a method for treating a mammal having a neuropathophysiological condition or suspected to develop said neuropathophysiological condition, comprising the step of administering to said mammal an inhibitor of CD38 NAD⁺ glycohydrolase activity.

The invention discloses a cosmetic anti-aging skincare composition containing nicotinamide mononucleotide (NMN). The NMN is taken as the active component and is used to produce the cosmetic anti-aging skincare composition. Because the NMN is the single substance in organism cells, the safety of the NMN is high. The provided skincare composition can prevent skin becoming rough and aged, reduce the skin wrinkles, and maintain the elasticity and bright color of the skin.

The invention discloses a novel method for preparing beta-nicotinamide mononucleotide (beta-NMN). According to the method, D-5-ribose phosphate, ATP and nicotinamide are used as raw materials, beta-nicotinamide mononucleotide can be efficiently and biologically synthesized by catalysis of immobilized whole-cell containing phosphoribosylpyrophosphate synthetase and nicotinamide phosphoribosyltransferase, and the concentration of the synthesized beta-nicotinamide mononucleotide can be 13.3g/L, so that the synthetic amount and conversion rate of beta-NMN enzymatic reaction can be increased, the immobilized whole-cell can be used repeatedly, and the reaction complexity and production cost can be reduced.

The invention provides a nicotinamide ribokinase mutant and application thereof. Compared with an amino acid sequence SEQID NO. 2, the difference of the amino acid sequence of the mutant is that the D45th, D58th, R161th and Y164 sites in the amino acid sequence SEQID NO. 2 are subjected to single mutation or in-pair combined mutation or three combined mutation or four combined mutation. Novel nicotinamide ribokinase mutant industrial enzyme is used for synthesis and preparation of beta-nicotinamide mononucleotide. The constructed nicotinamide ribokinase mutant enzyme has the advantages that the enzyme cost is low, the transformation time is short, and the process operation is simple, and has a broad large-scale industrial application prospect.

Compositions for addressing one or more of the effects of aging are described. The compositions comprise a first component comprising repair system activator(s) such as nicotinamide adenine dinucleotide (NAD+), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid riboside (NAR), 1-methylnicotinamide (MNM), cyclic adenosine monophosphate (cAMP) and combinations thereof; a second component comprising methyl donor(s), such as S-5'-adenosyl-L-methionine (SAM), methionine, betaine, choline, folate, vitamin B12, or combinations thereof; and a third component comprising antioxidant defense activators, such as H2O2, N2S, NaSH, Na2S, and several others, including combinations thereof.Methods of administering the disclosed compositions or separate formulations of repair system activator, methyl donors, and antioxidant defense activators are also disclosed.

The invention discloses a nicotinamide mononucleotide adenylyltransferase (Nmnat) mutant as well as a coding gene and an application thereof. The Nmnat mutant is obtained through point mutation of a sequence 2 in a sequence table and point mutation is mutation of at least one of the 119 site, the 149 site and the 59 site of the sequence. The Nmnat mutant with high catalytic activity is finally obtained through site-specific mutagenesis of the gene sequence of Nmnat. The mutant can be efficiently purified through a simple purification scheme, thus reducing the production cost of NAD (nicotinamide adenine dinucleotide) and improving the market competitiveness of corresponding products.

Disclosed is use of β-nicotinamide mononucleotide in the preparation of anti-aging drugs or health-care products. A single dose of the β-nicotinamide mononucleotide is 1-500 mg/Kg body weight/day, and the drug or health-care product is in the form of tablets, capsules, granules, aqueous solutions, enteric-coated preparations or injections.

The invention relates to the technical field of medicines. The present invention provides application of nicotinamide mononucleotide in preparation of medicines for promotion of nerve regeneration after cerebral ischemia, and the nicotinamide mononucleotide can be used as an active pharmaceutical ingredient and a pharmaceutically acceptable supplementary material for preparation of medicine compositions. The nicotinamide mononucleotide compound itself is an endogenous protective substance, and the available data do not report the adverse reaction, so that the nicotinamide mononucleotide as a medicine or a health product is high in safety and wide in therapeutic window.

New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, and essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.

The invention discloses a niacinamide ribose phosphate transferase for preparing NMN, a coding gene, a recombinant vector and application and belongs to the technical field of biology. The transferaseis protein of which the amino acid sequence is shown in pSEQ ID No.1 or pSEQ ID No.2 or pSEQ ID No.3 or pSEQ ID No4. The gene for coding the protein is cloned to an expression vector of escherichia coli, and a recombinant plasmid is established; then, the recombinant plasmid is converted into escherichia coli competent cells, a positive clone is selected, an expression strain of recombinant escherichia coli is obtained, and then liquid fermentation is conducted; in the fermentation process, the generated recombinant niacinamide ribose phosphate transferase is generated, and after a substrateis added, beta-nicotinamide mononucleotide can be generated. According to the transferase, NMN is conveniently and efficiently prepared, the fermentation technology is simple, the consumed time is short, the cost is low, the cost of obtaining NMN is 0.25-1.0 yuan/mg, compared with a traditional method, the cost can be lowered by above 90%, the yield reaches 51.75 mg/g of protein, and the economicbenefit is obvious.

The invention relates to the technical field of biological science and technology and provides a nicotinamide phosphoribosyltransferase mutant, a recombinant expression vector and a recombinant bacterium containing the mutant, and application in beta-nicotinamide mononucleotide synthesis. In the nicotinamide phosphoribosyltransferase mutant, 1 or 2 amino acid residues in amino acids selected fromamino acid equivalent positions of sites 156, 174, 203, 231, 242, 258, 272 and 405 in an amino acid sequence of a wild-type nicotinamide phosphoribosyltransferase are replaced by other amino acid residues. The nicotinamide phosphoribosyltransferase mutant disclosed by the invention increases the enzyme activity of the nicotinamide phosphoribosyltransferase, can promote synthesis of a beta-nicotinamide mononucleotide and can promote production of the beta-nicotinamide mononucleotide.

The invention provides a nicotinamide ribosyltransferase mutant and application thereof. Compared with an amino acid sequence SEQID NO. 2, the difference of the amino acid sequence of the mutant is that the R189th, S232th and R302th sites in the amino acid sequence SEQID NO. 2 are subjected to single mutation or in-pair combined mutation or three combined mutation. Novel nicotinamide ribosyltransferase mutant enzyme is used for synthesis and preparation of beta-nicotinamide mononucleotide. The constructed nicotinamide ribosyltransferase mutant enzyme has the advantages that the enzyme cost islow, the transformation time is short, and the process operation is simple, and has a broad large-scale industrial application prospect.

The invention discloses a combination process of nicotinamide riboside and its derivative with pyrroloquinoline quinone and its sodium salt. The combination process includes: combining any two or three of or all of NR (nicotinamide riboside) (a chloride, or nicotinamide riboside), NMN (beta-nicotinamide mononucleotide), NADH (nicotinamide adenine dinucleotide) and PQQ (pyrroloquinoline quinone disodium salt) into a formulation for making foods, health foods, cosmetics or drugs; the formulation is injected into the human body in external application, oral application or injection manner to takeeffect. The nicotinamide riboside and its derivative function to defy age; the pyrroloquinoline quinone and its sodium salt have the like function and are functionally complementary to nicotinamide riboside; the nicotinamide riboside or its derivative is combined with pyrroloquinoline quinone or its sodium salt into a formulation for making products, such as food additives, health foods, cosmetics and drugs, thereby delaying human senility, maintaining beauty or treating diseases.

The invention discloses a drug or health care product for preventing and treating hearing loss and relates to the technical field of biological medicine and health care products. Aiming at the defects that there are not many drugs for treating hearing loss in the market currently, the treatment effect is poor, and health care products with the corresponding function are unavailable, the effective and well-targeted drug for preventing and treating hearing loss and the corresponding health care product, especially the drug which has a special effect on sensorineural hearing loss including age-related hearing loss, noise induced hearing loss and sudden hearing loss and the corresponding health care product are provided. The drug or health care product contains the active constituent nicotinamide mononucleotide. The drug or health care product has the advantages of being capable of becoming effective quickly, high in treatment effect, stable in efficacy, free of toxic or side effect on human body and the like.

The invention relates to the field of biological medicines, and in particular to a composition of beta-nicotinamide mononucleotide or a beta-nicotinamide mononucleotide precursor, and a preparation method and application of the composition. The composition comprises the following raw materials in percentage by weight: 0.001 to 25 percent of beta-nicotinamide mononucleotide or a precursor thereof,0 to 20 percent of a transdermal absorption enhancer, 2 to 50 percent of an auxiliary component and the balance of water. After being absorbed by a human body in a mode of transdermal administration or external administration, the composition can exert effects of improving internal functions of a human body, improving metabolism of a human body or improving epidermal functions of a human body, andresisting skin inflammation, allergy and skin aging. Through the mode of transdermal administration and external administration, metabolic burden of liver and kidney can be avoided, blood concentration can be kept constant, and administration is convenient.

A medication having nicotinamide mononucleotide as the active ingredient, and the use of nicotinamide mononucleotide in preparing medications for the prevention and treatment of arteriosclerosis and cardiovascular and cerebrovascular diseases caused by arteriosclerosis.

The invention discloses a nicotinamide mononucleotide adenylyl transferase gene. The nucleotide sequence of the gene is shown as SEQ ID NO: 1. The amino acid sequence of the gene is shown as SEQ ID NO:2. The invention also discloses an expression vector; a method comprises the steps of using the expression vector for transforming the host cell, culturing a transformant, and acquiring nicotinamide mononucleotide adenylyl transferase gene from culture, so as to obtain the recombinant nicotinamide mononucleotide adenylyl transferase gene. The invention discloses application of the recombinant nicotinamide mononucleotide adenylyl transferase gene to in vitro conversion of nicotinamide mononucleoside NMN into nicotinamide adenine dinucleotide NAD<+>. The invention also discloses a synthesis method of nicotinamide adenine dinucleotide NAD<+>. The method uses nicotinamide mononucleoside NMN as raw material to generate nicotinamide adenine dinucleotide NAD<+> under the action of the recombinant nicotinamide mononucleotide adenylyl transferase gene.

The invention relates to the technical fields of biopharmacy and biochemical industry, and in particular relates to an enzyme composition for preparing nicotinamide mononucleotide and a method for preparing the nicotinamide mononucleotide by an enzymatic process. The enzyme composition is composed of adenosine kinase, adenine phosphoribosyl transferase and nicotinamide phosphoribosyl transferase.The three enzymes provided by the invention can be reasonably combined for efficient catalytic preparation of the nicotinamide mononucleotide. The enzyme composition provided by the invention can be recycled, has low costs, saves energy and protects the environment; the method for preparing the nicotinamide mononucleotide by the enzymatic process provided by the invention uses adenosine as a substrate, the enzyme composition is added, so that the nicotinamide mononucleotide can be prepared at low cost, safely and reliably, the cost of a current route can be reduced, and the method can be suitable for large-scale production and provides guarantee for the use of the nicotinamide mononucleotide in the fields of biocatalysis and drugs.